• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Best evidence in critical care medicine. Intensive vs conventional blood glucose control in critically ill patients.
【24h】

Best evidence in critical care medicine. Intensive vs conventional blood glucose control in critically ill patients.

机译：重症监护医学的最佳证据。重症患者的强化血糖控制与常规血糖控制。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hyperglycemiais common during critical illness and has been identified as a modifiable risk factor for increased morbidity and mortality in critically ill patients. Data from selected clinical trials suggest that intensive insulin therapy (ITT) and tight glycemic control (TGC) achieve a clinical benefit when targeting blood glucose (BG) in the range of 4.4-6.1 mmol L~-1. However, reports of recently conducted randomized trials have shown conflicting results. Consequently, the NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) trial was designed as a pragmatic multi-national multi-centre randomized "effectiveness" trial to evaluate the impact of IIT to achieve TGC on 90-day all cause mortality and several secondary morbidity outcomes. The NICE-SUGAR trial aimed to resolve existing concerns about the applicability of IIT to achieve TGC in critical illness. This article considers the NICE-SUGAR trial and discusses, its key findings in the context of the published literature.
机译：高血糖症在重症患者中很常见，已被确定为重症患者发病率和死亡率增加的可改变的危险因素。来自某些临床试验的数据表明，当靶向血糖（BG）介于4.4-6.1 mmol L〜-1范围内时，强化胰岛素治疗（ITT）和严格的血糖控制（TGC）可获得临床益处。但是，最近进行的随机试验的报告显示出矛盾的结果。因此，NICE-SUGAR（使用葡萄糖算法法规在重症监护评估和生存中的血糖正常）试验被设计为实用的多国多中心随机“有效性”试验，旨在评估IIT对90天全天TGC的影响会导致死亡率和一些继发性发病结果。 NICE-SUGAR试验旨在解决有关IIT在危重病中实现TGC适用性的现有问题。本文考虑了NICE-SUGAR试验并在已发表文献的背景下讨论了其主要发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号